SMB-1 is a novel KV7 channel modulator that selectively inhibits KV7.2 and activates KV7.4, demonstrating that the retigabine binding site can accommodate compounds with opposite effects on different KV7 subtypes.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for retigabine-site ligands enabling opposite KV7 subtype effects; leaves open clinical translation in cardiovascular or neurological settings.
Blom et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: